Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?
Medical – Clinical – Research · 28.02.2026 · 2 (2)
DOI: 10.52106/3069-9088.1018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical – Clinical – Research, online erschienen am 28.02.2026. Verfasst von Hans Klingemann und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Infusion of engineered immune cells has shown some therapeutic efficacy in cancer patients but high costs and in some cases more significant side effects are supporting the need for new approaches. Here we present a perspective on cellular bio-lysate from NK-92 cells. These cells rapidly proliferate and a method to extract their cytotoxic bio-lysate for clinical application has been developed. The bio-lysate has cross- species anti-tumor activity and also provides a durable, vaccine-like effect.
Zitieren
APA
Klingemann, H., & Chinnapen, H. (2026). Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?. Medical – Clinical – Research, 2(2). https://doi.org/10.52106/3069-9088.1018
Vancouver
Klingemann H, Chinnapen H. Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?. Medical – Clinical – Research. 2026;2(2). doi:10.52106/3069-9088.1018
BibTeX
@article{Klingemann2026,
author = {Klingemann, Hans and Chinnapen, Himani},
title = {Immunotherapy with Natural Killer Cells: Are Intact Cells Required, or Can Their Bio-Lysate Achieve Therapeutic Efficacy?},
journal = {Medical – Clinical – Research},
year = {2026},
volume = {2},
number = {2},
doi = {10.52106/3069-9088.1018}
}
EUVIMED